226 filings
Page 3 of 12
6-K/A
k5p1iut5eocf8
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
6-K
79wr6q5 s1
22 Aug 22
ObsEva Receives Nasdaq Non-Compliance Notice
6:08am
6-K
6y5 heygf5fggp6
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
F-3MEF
fqjvc80p
3 Aug 22
Registration statement to add securities to prior F-3 registration
4:25pm
6-K
rha chc359ycxpo0iw1v
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
v58l941 kacuh
29 Jul 22
ObsEva Announces Management Change
7:06am
6-K
5jjybhkncpzt4ly5p42
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
1vl2665xvjduhndj
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
j600d nt4fo7o
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
053og
27 May 22
ObsEva Announces Corporate Updates
4:56pm
6-K
9db9wt995
19 May 22
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
7:05am
6-K
334nkz88l93amnuhcts
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
kj8lyzia
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
10fxzeb
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
e9c3rr0yjj h2x
7 Apr 22
ObsEva Annual General Meeting 2022
7:01am
6-K
5tjmh0aa8yatjtvgli
31 Mar 22
ObsEva Annual Report 2021
7:05am
6-K
k5egxy
22 Mar 22
Current report (foreign)
7:28am
6-K
f0ci2h8bf40w
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
424B7
atse1p9v
3 Mar 22
Prospectus with selling stockholder info
4:43pm